Skip to Main Content

Close

AACR Journals
For Authors
About Us
Article Collections
COVID-19
Webinars

header search

search input Search input auto suggest

Search

Advanced Search

Register

Sign In

Menu

About
Articles
For Authors
Alerts
News
COVID-19
Webinars

Skip Nav Destination

Issues

Select Year

Issue

Volume 7, Issue 2_Supplement

1 February 2019

ISSN 2326-6066

EISSN 2326-6074

In this Issue

Other Topics
Trials in Progress
Clinical Trials of Cancer Immunotherapies
Keynote Address
Maintenance of Immune Balance: Effects of Targeted and Immune Therapies
Genetically Engineered T-cells
Mutational Analysis and Predicting Response to Immunotherapy
Tackling the Tumor Microenvironment: Beyond T-cells
Convergence of Technology and Cancer Immunotherapy
Regulating T-cells and Their Response to Cancer
William B. Coley Lecture
Novel Vaccine Platforms and Combinations
Microbiome and Metabolism

Search within issue:

Search within issue

Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY

Trials in Progress

Clinical Trials of Cancer Immunotherapies

Keynote Address

Maintenance of Immune Balance: Effects of Targeted and Immune Therapies

Genetically Engineered T-cells

Mutational Analysis and Predicting Response to Immunotherapy

Tackling the Tumor Microenvironment: Beyond T-cells

Convergence of Technology and Cancer Immunotherapy

Regulating T-cells and Their Response to Cancer

William B. Coley Lecture

Novel Vaccine Platforms and Combinations

Microbiome and Metabolism

All Issues

Email alerts

Online First Alert

eTOC Alert

Latest
Most Read
Most Cited

Preclinical Characterization and Phase 1 Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies

A population of TIM4+FOLR2+ macrophages localized in tertiary lymphoid structures correlates to an active immune infiltrate across several cancer types

Immune phenotypes and target antigens of clonally expanded bone marrow T cells in treatment-naïve multiple myeloma

Secreted Fas decoys enhance the antitumor activity of engineered and bystander T cells in Fas ligand–expressing solid tumors

Issues
Online First
News

Twitter

Online ISSN 2326-6074
Print ISSN 2326-6066

AACR Journals

Blood Cancer Discovery
Cancer Discovery
Cancer Epidemiology, Biomarkers, & Prevention
Cancer Immunology Research
Cancer Prevention Research
Cancer Research
Cancer Research Communications
Clinical Cancer Research
Molecular Cancer Research
Molecular Cancer Therapeutics

Info for Advertisers
Info for Librarians
Privacy Policy

Twitter
LinkedIn
Facebook
Youtube

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.

Accept